Clinical Trial Update: Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update indicating a Phase 1/Phase 2 study of ribociclib, tucatinib, and trastuzumab for HER2-positive breast cancer is currently recruiting acros…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• KISQALI (ribociclib)
• Tukysa (tucatinib)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 | Phase 1, Phase 2 | Status: RECRUITING